Cerus hematology news

Cerus will reduce its headcount by 31 (30%) to 75 to reduce cash burn. The cuts will come mainly from development and general administration and include CFO William Dawson. Controller Kevin Green will serve as chief accounting officer. The company's Intercept Blood System is in Phase III testing in the U.S to inactivate blood-borne pathogens for plasma and platelets. The system, which uses psoralen S-59 light-activated compound, is marketed in over 30 countries in Europe and Asia, with 2008 sales of $15.5 million. ...